Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
265 | Publisher: Global Research & Data Services
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Traumatic Brain Injury - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H1 2015’, provides an overview of the Traumatic Brain Injury’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Traumatic Brain Injury Overview 10 Therapeutics Development 11 Pipeline Products for Traumatic Brain Injury - Overview 11 Pipeline Products for Traumatic Brain Injury - Comparative Analysis 12 Traumatic Brain Injury - Therapeutics under Development by Companies 13 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 18 Traumatic Brain Injury - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Traumatic Brain Injury - Products under Development by Companies 23 Traumatic Brain Injury - Products under Investigation by Universities/Institutes 28 Traumatic Brain Injury - Companies Involved in Therapeutics Development 29 Adamas Pharmaceuticals, Inc. 29 ALSP, Inc. 30 Amarantus Bioscience Holdings, Inc. 31 Athersys, Inc. 32 BHR Pharma, LLC 33 Cognosci, Inc. 34 Concert Pharmaceuticals, Inc. 35 Euroscreen S.A. 36 Grupo Ferrer Internacional, S.A. 37 International Stem Cell Corporation 38 Io Therapeutics, Inc. 39 Ischemix 40 Karyopharm Therapeutics, Inc. 41 Kyorin Pharmaceutical Co., Ltd. 42 Levolta Pharmaceuticals, Inc. 43 Lixte Biotechnology Holdings, Inc. 44 Lpath, Inc. 45 MandalMed, Inc. 46 Mapreg S.A.S. 47 Mnemosyne Pharmaceuticals, Inc. 48 NeoStem, Inc. 49 Neuralstem, Inc. 50 Neuren Pharmaceuticals Limited 51 NeuroHealing Pharmaceuticals Inc. 52 NeuroNascent, Inc. 53 Neuronax SAS 54 NeuroVive Pharmaceutical AB 55 Omeros Corporation 56 PharmatrophiX, Inc. 57 Phylogica Limited 58 Prevacus, Inc. 59 PsychoGenics, Inc. 60 QR Pharma, Inc. 61 RAPID Pharmaceuticals AG 62 RegeneRx Biopharmaceuticals, Inc. 63 Remedy Pharmaceuticals, Inc. 64 Sage Therapeutics 65 SanBio, Inc. 66 STATegics, Inc. 67 SynZyme Technologies, LLC 68 Tetra Discovery Partners LLC 69 vasopharm GmbH 70 VG Life Sciences, Inc. 71 Traumatic Brain Injury - Therapeutics Assessment 72 Assessment by Monotherapy Products 72 Assessment by Combination Products 73 Assessment by Target 74 Assessment by Mechanism of Action 77 Assessment by Route of Administration 80 Assessment by Molecule Type 82 Drug Profiles 84 2-DG - Drug Profile 84 ALP-496 - Drug Profile 86 amantadine hydrochloride ER - Drug Profile 88 AMR-001 - Drug Profile 90 AMRS-001 - Drug Profile 92 apomorphine hydrochloride - Drug Profile 94 AVL-8168 - Drug Profile 96 BHR-310 - Drug Profile 97 C-10068 - Drug Profile 98 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 99 CHEC-7 - Drug Profile 100 CHEC-9 - Drug Profile 101 CMX-2043 - Drug Profile 103 CNB-001 - Drug Profile 105 COG-1410 - Drug Profile 107 cyclosporine - Drug Profile 109 dexamethasone acetate + melatonin - Drug Profile 112 EPO-Variant - Drug Profile 113 ESN-502 - Drug Profile 114 felbamate - Drug Profile 115 FIB-117 - Drug Profile 116 glyburide - Drug Profile 117 HBN-1 - Drug Profile 119 HBN-2 - Drug Profile 120 ibudilast - Drug Profile 121 ICCN-100 - Drug Profile 123 IRX-4204 - Drug Profile 124 KPT-350 - Drug Profile 126 LB-201 - Drug Profile 127 LB-205 - Drug Profile 128 LM11A-31 - Drug Profile 129 Lpathomab - Drug Profile 130 MAP-4343 - Drug Profile 131 MultiStem - Drug Profile 132 ND-478 - Drug Profile 135 NNI-370 - Drug Profile 136 NNZ-2591 - Drug Profile 137 NSI-189 - Drug Profile 139 NSI-566 - Drug Profile 140 NVP-019 - Drug Profile 142 NVX-428 - Drug Profile 143 NX-210 - Drug Profile 144 Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 145 PGI-02776 - Drug Profile 146 Posiphen - Drug Profile 148 progesterone - Drug Profile 150 PRV-002 - Drug Profile 151 PYC-35 - Drug Profile 152 PYC-36 - Drug Profile 153 PYC-38 - Drug Profile 154 PYC-98 - Drug Profile 155 R-503 - Drug Profile 156 RAP-701 - Drug Profile 158 RGN-352 - Drug Profile 159 SAGE-547 - Drug Profile 161 SB-623 - Drug Profile 163 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 164 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 165 Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 166 Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer’s Disease - Drug Profile 167 Small Molecule to Inhibit PDE4 for Traumatic Brain Injury - Drug Profile 168 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 169 Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile 170 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 171 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 172 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 173 Stem Cell Therapy for Parkinson’s Disease, Traumatic Brain Injury and Stroke - Drug Profile 174 Stem Cell Therapy for Traumatic Spinal Cord Injury and Brain Injury - Drug Profile 176 STSE-15 - Drug Profile 177 TBI-121 - Drug Profile 178 TBI-122 - Drug Profile 179 TBI-123 - Drug Profile 180 trofinetide - Drug Profile 181 UH-0113 - Drug Profile 183 UH-0213 - Drug Profile 184 VAS-203 - Drug Profile 185 VG-1177 - Drug Profile 187 VitalHeme - Drug Profile 189 VOLT-02 - Drug Profile 191 Traumatic Brain Injury - Recent Pipeline Updates 192 Traumatic Brain Injury - Dormant Projects 245 Traumatic Brain Injury - Discontinued Products 249 Traumatic Brain Injury - Product Development Milestones 250 Featured News & Press Releases 250 Appendix 258 Methodology 258 Coverage 258 Secondary Research 258 Primary Research 258 Expert Panel Validation 258 Contact Us 258 Disclaimer 259
List of Tables Number of Products under Development for Traumatic Brain Injury, H1 2015 17 Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2015 18 Number of Products under Development by Companies, H1 2015 20 Number of Products under Development by Companies, H1 2015 (Contd..1) 21 Number of Products under Development by Companies, H1 2015 (Contd..2) 22 Number of Products under Development by Companies, H1 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2015 24 Comparative Analysis by Late Stage Development, H1 2015 25 Comparative Analysis by Clinical Stage Development, H1 2015 26 Comparative Analysis by Early Stage Development, H1 2015 27 Comparative Analysis by Unknown Stage Development, H1 2015 28 Products under Development by Companies, H1 2015 29 Products under Development by Companies, H1 2015 (Contd..1) 30 Products under Development by Companies, H1 2015 (Contd..2) 31 Products under Development by Companies, H1 2015 (Contd..3) 32 Products under Development by Companies, H1 2015 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2015 34 Traumatic Brain Injury - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 35 Traumatic Brain Injury - Pipeline by ALSP, Inc., H1 2015 36 Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 37 Traumatic Brain Injury - Pipeline by Athersys, Inc., H1 2015 38 Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H1 2015 39 Traumatic Brain Injury - Pipeline by Cognosci, Inc., H1 2015 40 Traumatic Brain Injury - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41 Traumatic Brain Injury - Pipeline by Euroscreen S.A., H1 2015 42 Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 43 Traumatic Brain Injury - Pipeline by International Stem Cell Corporation, H1 2015 44 Traumatic Brain Injury - Pipeline by Io Therapeutics, Inc., H1 2015 45 Traumatic Brain Injury - Pipeline by Ischemix, H1 2015 46 Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 47 Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 48 Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H1 2015 49 Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 50 Traumatic Brain Injury - Pipeline by Lpath, Inc., H1 2015 51 Traumatic Brain Injury - Pipeline by MandalMed, Inc., H1 2015 52 Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H1 2015 53 Traumatic Brain Injury - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 54 Traumatic Brain Injury - Pipeline by NeoStem, Inc., H1 2015 55 Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H1 2015 56 Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 57 Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2015 58 Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H1 2015 59 Traumatic Brain Injury - Pipeline by Neuronax SAS, H1 2015 60 Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2015 61 Traumatic Brain Injury - Pipeline by Omeros Corporation, H1 2015 62 Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H1 2015 63 Traumatic Brain Injury - Pipeline by Phylogica Limited, H1 2015 64 Traumatic Brain Injury - Pipeline by Prevacus, Inc., H1 2015 65 Traumatic Brain Injury - Pipeline by PsychoGenics, Inc., H1 2015 66 Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H1 2015 67 Traumatic Brain Injury - Pipeline by RAPID Pharmaceuticals AG, H1 2015 68 Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 69 Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 70 Traumatic Brain Injury - Pipeline by Sage Therapeutics, H1 2015 71 Traumatic Brain Injury - Pipeline by SanBio, Inc., H1 2015 72 Traumatic Brain Injury - Pipeline by STATegics, Inc., H1 2015 73 Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H1 2015 74 Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2015 75 Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2015 76 Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H1 2015 77 Assessment by Monotherapy Products, H1 2015 78 Assessment by Combination Products, H1 2015 79 Number of Products by Stage and Target, H1 2015 81 Number of Products by Stage and Mechanism of Action, H1 2015 84 Number of Products by Stage and Route of Administration, H1 2015 87 Number of Products by Stage and Molecule Type, H1 2015 89 Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H1 2015 198 Traumatic Brain Injury - Dormant Projects, H1 2015 251 Traumatic Brain Injury - Dormant Projects (Contd..1), H1 2015 252 Traumatic Brain Injury - Dormant Projects (Contd..2), H1 2015 253 Traumatic Brain Injury - Dormant Projects (Contd..3), H1 2015 254 Traumatic Brain Injury - Discontinued Products, H1 2015 255
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
